HC Wainwright Predicts Acumen Pharmaceuticals FY2029 EPS at $2.03, Maintains 'Buy' Rating

Summary

HC Wainwright analysts forecast Acumen Pharmaceuticals (NASDAQ: ABOS) will report earnings of $2.03 per share for the fiscal year 2029 and maintain a ‘buy’ rating with a target price of $11.00. This contrasts with the current consensus expectation of $1.56 per share. Recently, Acumen reported quarterly earnings of $0.62 per share, missing expectations. UBS has lowered its target price from $6.00 to $4.00 while maintaining a ‘buy’ rating. Acumen’s stock opened at $1.19 with a market cap of $71.5 million and significant institutional holdings.Market Beat

Impact Analysis

The event is classified at the Company Level, as it directly pertains to Acumen Pharmaceuticals’ projected financial performance and analyst ratings. The prediction by HC Wainwright suggests optimism about the company’s future earnings, despite recent earnings misses and UBS lowering the target price. First-order effects include investor reassessment of Acumen’s growth potential, possibly leading to increased buying interest given the ‘buy’ ratings. Second-order effects might involve broader implications for investor confidence in biotech firms focused on Alzheimer’s disease treatments. Investment opportunities could arise from potential stock price appreciation if Acumen meets or exceeds future earnings expectations. Risks involve the company failing to achieve projected earnings and potential volatility due to differing analyst opinions.Market Beat+ 2